Douglass Winthrop Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Douglass Winthrop Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$376K	Hold	841	–	–	0.01%	240
2025 Q4	$381K	Sell	841 -68	-7%	-$29.3K	0.01%	249
2025 Q3	$356K	Buy	909 +41	+5%	+$17.1K	0.01%	242
2025 Q2	$386K	Hold	868	–	–	0.01%	215
2025 Q1	$421K	Sell	868 -50	-5%	-$23.3K	0.01%	206
2024 Q4	$370K	Hold	918	–	–	0.01%	230
2024 Q3	$427K	Sell	918 -24	-3%	-$11.5K	0.01%	213
2024 Q2	$442K	Buy	942 +5	+0.5%	+$2.17K	0.01%	205
2024 Q1	$392K	Hold	937	–	–	0.01%	208
2023 Q4	$381K	Hold	937	–	–	0.01%	196
2023 Q3	$326K	Buy	937 +19	+2%	+$6.64K	0.01%	195
2023 Q2	$323K	Hold	918	–	–	0.01%	202
2023 Q1	$289K	Hold	918	–	–	0.01%	207
2022 Q4	$265K	Hold	918	–	–	0.01%	215
2022 Q3	$266K	Hold	918	–	–	0.01%	210
2022 Q2	$259K	Hold	918	–	–	0.01%	223
2022 Q1	$240K	Hold	918	–	–	0.01%	242
2021 Q4	$202K	Buy	+918	New	+$179K	﹤0.01%	266
2021 Q1	–	Sell	-954	Closed	-$225K	–	276
2020 Q4	$225K	Sell	954 -215	-18%	-$49.3K	0.01%	247
2020 Q3	$318K	Sell	1,169 -200	-15%	-$55.2K	0.01%	217
2020 Q2	$397K	Sell	1,369 -74	-5%	-$20.1K	0.01%	187
2020 Q1	$343K	Sell	1,443 -101	-7%	-$23.2K	0.02%	188
2019 Q4	$338K	Hold	1,544	–	–	0.01%	225
2019 Q3	$262K	Hold	1,544	–	–	0.01%	230
2019 Q2	$283K	Hold	1,544	–	–	0.01%	228
2019 Q1	$284K	Hold	1,544	–	–	0.01%	211
2018 Q4	$256K	Sell	1,544 -106	-6%	-$18.4K	0.01%	217
2018 Q3	$318K	Sell	1,650 -200	-11%	-$35.6K	0.01%	211
2018 Q2	$314K	Sell	1,850 -265	-13%	-$41.1K	0.01%	234
2018 Q1	$345K	Sell	2,115 -9	-0.4%	-$1.47K	0.02%	220
2017 Q4	$318K	Hold	2,124	–	–	0.02%	201
2017 Q3	$323K	Buy	2,124 +24	+1%	+$3.61K	0.02%	196
2017 Q2	$271K	Buy	+2,100	New	+$253K	0.02%	219
2016 Q4	–	Sell	-3,000	Closed	-$262K	–	246
2016 Q3	$262K	Buy	3,000 +500	+20%	+$47.3K	0.02%	214
2016 Q2	$215K	Buy	+2,500	New	+$216K	0.02%	227
2016 Q1	–	Sell	-2,500	Closed	-$315K	–	239
2015 Q4	$315K	Hold	2,500	–	–	0.02%	187
2015 Q3	$260K	Hold	2,500	–	–	0.02%	207
2015 Q2	$295K	Hold	2,500	–	–	0.02%	207
2015 Q1	$295K	Buy	+2,500	New	+$300K	0.02%	207

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Douglass Winthrop Advisors's VRTX Position: Q1 2026 in Review

Douglass Winthrop Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 841 shares worth $376K. The position accounts for 0.01% of the portfolio, ranked #240.

Douglass Winthrop Advisors first reported a position in VRTX in Q1 2015 and has held it in 39 quarters since. The position peaked at $442K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Douglass Winthrop Advisors held 841 shares of Vertex Pharmaceuticals worth $376K as of Q1 2026.
Douglass Winthrop Advisors left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Douglass Winthrop Advisors's portfolio in Q1 2026, its #240 holding.
Douglass Winthrop Advisors first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 39 quarters since.
Douglass Winthrop Advisors's Vertex Pharmaceuticals position peaked at $442K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Douglass Winthrop Advisors's 13F filing for Q1 2026, filed 14 May 2026.